453566-15-9 Usage
General Description
3-Bromo-5-cyanobenzoic acid methyl ester is a chemical compound with the molecular formula C10H7BrNO2. It is a methyl ester derivative of 3-bromo-5-cyanobenzoic acid and is commonly used in organic synthesis and pharmaceutical research as a building block for the preparation of various pharmaceutical compounds and agrochemicals. 3-BroMo-5-cyanobenzoic acid Methyl ester is a pale yellow solid with a melting point of 146-149°C and is soluble in organic solvents such as acetone and ethyl acetate. It is important to handle this compound with caution as it may be harmful if ingested, inhaled, or comes into contact with skin and eyes.
Check Digit Verification of cas no
The CAS Registry Mumber 453566-15-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,5,3,5,6 and 6 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 453566-15:
(8*4)+(7*5)+(6*3)+(5*5)+(4*6)+(3*6)+(2*1)+(1*5)=159
159 % 10 = 9
So 453566-15-9 is a valid CAS Registry Number.
453566-15-9Relevant articles and documents
MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS
-
, (2020/10/18)
Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
-
, (2008/06/13)
The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
